BioSpace

On the heels of a serious adverse event in a Phase 2 alcohol use disorder trial of its lead drug candidate, Tempero Bio is shutting down. Learn more in our layoff tracker. #layoffs #biopharma #biospace https://hubs.li/Q04dmfCB0

Neal and Azbee awards have validated our approach to reporting on the industry at a time of unprecedented shifts at the FDA and other federal agencies. #editorial #FDA #biopharma #journalism #biospace https://hubs.li/Q04dlqX50

Daiichi Sankyo’s full-year report was originally scheduled for April 27 but has now been pushed back to May 11. That same day, the pharma expects to release its five-year business plan. #pharma #biospace https://hubs.li/Q04dlsp20

Pfizer’s decision to cut its early-stage cancer asset was due to “strategic business reasons” and not driven by safety or efficacy concerns. #pharma #biospace https://hubs.li/Q04dlrX80

Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year. #IPO #biospace https://hubs.li/Q04dl8sk0

The FDA is signaling change, but actual success depends on more than simply bringing in a new leader at the Center for Biologics Evaluation and Research; it requires accountability, transparency and consistent action. #opinion #FDA #CBER #biospace https://hubs.li/Q04dlq1m0

ICYMI: Our poll closes in a few hours. If you haven't cast your vote yet, we'd love to hear from you! You can also answer a few questions about experience you've had doing work for free during interviews in our SurveyMonkey survey. https://lnkd.in/gut-7g6W

Of the 17 companies that were implored by the White House last July to apply Most Favored Nation pricing to their drugs, Regeneron is the last to agree—the same day the FDA greenlit its gene therapy for hearing loss in kids. #drugpricing #genetherapy #biospace https://hubs.li/Q04dl5vq0

The takeover will give Amneal control of four facilities to manufacture biosimilars for a planned wave of launches in the coming years. #manufacturing #biospace https://hubs.li/Q04dflTK0

Chief Scientific Officer Pedro Beltran will succeed Eli Wallace as CEO of BridgeBio Oncology Therapeutics, as the board eyes a busy period of clinical advancement in the RAS oncology space. #leadership #oncology #biospace https://hubs.li/Q04dddrL0